177 related articles for article (PubMed ID: 30429031)
1. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
Cardona AF; Rojas L; Zatarain-Barrón ZL; Freitas HC; Granados ST; Castillo O; Oblitas G; Corrales L; Castro CD; Ruiz-Patiño A; Martín C; Pérez MA; González L; Chirinos L; Vargas C; Carranza H; Otero J; Rodriguez J; Rodriguez J; Archila P; Lema M; Acosta Madiedo J; Karachaliu N; Wills B; Pino LE; de Lima V; Rosell R; Arrieta O;
Lung Cancer; 2018 Nov; 125():265-272. PubMed ID: 30429031
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
[TBL] [Abstract][Full Text] [Related]
3. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
[TBL] [Abstract][Full Text] [Related]
4. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
She Y; Li S; Deng J; Ren Y; Zhao M; Zhong Y; He Y; Chen Q; Zhao D; Zhu Y; Hou L; Wu C; Xie D; Chen C
Eur J Cancer; 2022 Dec; 177():53-62. PubMed ID: 36323053
[TBL] [Abstract][Full Text] [Related]
6. An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
Corrales-Rodríguez L; Arrieta O; Mas L; Báez-Saldaña R; Castillo-Fernández O; Blais N; Martín C; Juárez M; Khanna P; Ramos-Esquivel A; Bacon L; Rojas L; Wills B; Oblitas G; Pérez MA; Cuello M; Cardona AF;
Lung Cancer; 2017 Nov; 113():30-36. PubMed ID: 29110845
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer.
Thamrongjirapat T; Muntham D; Incharoen P; Trachu N; Sae-Lim P; Sarachai N; Khiewngam K; Monnamo N; Kantathut N; Ngodngamthaweesuk M; Ativitavas T; Chansriwong P; Nitiwarangkul C; Ruangkanchanasetr R; Kositwattanarerk A; Sirachainan E; Dejthevaporn T; Reungwetwattana T
BMC Cancer; 2024 Feb; 24(1):200. PubMed ID: 38347487
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.
Bazhenova L; Minchom A; Viteri S; Bauml JM; Ou SI; Gadgeel SM; Trigo JM; Backenroth D; Li T; Londhe A; Mahadevia P; Girard N
Lung Cancer; 2021 Dec; 162():154-161. PubMed ID: 34818606
[TBL] [Abstract][Full Text] [Related]
10. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
Morita C; Yoshida T; Shirasawa M; Masuda K; Matsumoto Y; Shinno Y; Yagishita S; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Motoi N; Yatabe Y; Ohe Y
Sci Rep; 2021 Sep; 11(1):18762. PubMed ID: 34548567
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
13. Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations.
Chen T; Wen J; Li Y; Deng J; Zhong Y; Hou L; She Y; Xie D; Chen C
Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38001033
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region].
Ma XM; Cao YZ; Ji WL; Zhao F; Fang XZ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):663-666. PubMed ID: 29263509
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Multigene Mutations in Lung Adenocarcinoma in Zunyi.
Ma Q; Ma D; Lin M; Gong Y; Han X; Chen Y; Tang Z; Liu M
Biomed Res Int; 2021; 2021():9939065. PubMed ID: 34136575
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations.
Hayashi T; Kohsaka S; Takamochi K; Hara K; Kishikawa S; Sano K; Takahashi F; Suehara Y; Saito T; Takahashi K; Suzuki K; Yao T
Hum Pathol; 2020 Sep; 103():42-51. PubMed ID: 32673682
[TBL] [Abstract][Full Text] [Related]
17. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
19. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Takada K; Toyokawa G; Tagawa T; Kohashi K; Shimokawa M; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
Lung Cancer; 2018 Feb; 116():1-6. PubMed ID: 29413045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
